Skip to main content
SpringerLink
Log in

Edoxaban affects TRAP-dependent platelet aggregation

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor. However, it is still not fully understood if and how edoxaban impacts platelet function. This prospective study aimed to assess in vitro platelet function in patients with atrial fibrillation (AF) receiving edoxaban. It was a single centre study quantifying platelet aggregation in 20 patients treated with edoxaban by light transmission aggregometry. The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower 2 h after taking edoxaban compared to baseline value (44.7 ± 32.03% vs. 73.3 ± 25.55%; p < 0.0001). In addition, we did not find any significant difference in results between the patient groups.

The TRAP-induced platelet aggregation is reduced in non-valvular AF patients receiving edoxaban.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Oung AB (2018) Edoxaban (Savaysa) for the prevention of thromboembolic events. Am Fam Physician 97:529–530

    PubMed  Google Scholar 

  2. Cuker A, Husseinzadeh H (2015) Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 39:288–294

    Article  CAS  Google Scholar 

  3. Burnett AE, Mahan CE, Vazquez SR et al (2016) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41:206–232

    Article  CAS  Google Scholar 

  4. Santos-Gallego CG, Badimon L, Badimón J (2014) Perspectives: direct and specific inhibition of factor Xa: an emerging therapeutic strategy for atherothrombotic disease. Eur Heart J Suppl 16:A56–A60

    Article  CAS  Google Scholar 

  5. Plitt A, Giugliano RP (2014) Edoxaban: review of pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther 19:409–416

    Article  CAS  Google Scholar 

  6. Mann KG, Brummel K, Butenas S (2003) What is all that thrombin for? J Thromb Haemost 1:1504–1514

    Article  CAS  Google Scholar 

  7. Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ (2019) Dual versus triple antithrombotic therapy: is there a role for direct oral anticoagulants in arterial thrombosis? Drugs Today (Barc) 55:197–214

    Article  CAS  Google Scholar 

  8. Michelson AD, Ellis P, Barnard MR et al (1991) Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an in vivo wound. Blood 77:770–779

    Article  CAS  Google Scholar 

  9. Coughlin SR (2000) Thrombin signaling and protease activated receptors. Nature 407:258–264

    Article  CAS  Google Scholar 

  10. Harrison P, Mackie I, Mumford A et al (2011) Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 155:30–44

    Article  CAS  Google Scholar 

  11. Ivanciu L, Krishnaswamy S, Camire RM (2014) New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 124:1705–1714

    Article  CAS  Google Scholar 

  12. Ivanciu L, Stalker TJ (2015) Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo. J Thromb Haemost 13:1949–1959

    Article  CAS  Google Scholar 

  13. Rahman SM, Eichinger CD, Hlady V (2018) Effects of upstream shear forces on priming of platelets for downstream adhesion and activation. Acta Biomater 73:228–235

    Article  Google Scholar 

  14. Davey MG, Luscher EF (1967) Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 216:857–858

    Article  CAS  Google Scholar 

  15. Sreiff MB, Agnelli G, Connors JM et al (2016) Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis 41:32–67

    Article  CAS  Google Scholar 

  16. Nehaj F, Sokol J, Ivankova J et al (2018) First Evidence: TRAP-induced platelet aggregation is reduced in patients receiving xabans. Clin Appl Thromb Hemost 24:914–919

    Article  CAS  Google Scholar 

  17. Nehaj F, Sokol J, Mokan M et al (2018) Thrombin receptor agonist peptide-induced platelet aggregation is reduced in patients receiving dabigatran. Clin Appl Thromb Hemost 24:268–272

    Article  CAS  Google Scholar 

  18. Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377:1319–1330

    Article  CAS  Google Scholar 

  19. Santos-Gallego CG, Bayón J, Badimón JJ (2010) Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med 12(3):274–291

    Article  Google Scholar 

Download references

Acknowledgements

The study was supported by Vedecká Grantová Agentúra MŠVVaŠ SR a SAV (Grant VEGA 1/0187/17) and Agentúra na Podporu Výskumu a Vývoja (Grant APVV-17-0054).

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia

    Frantisek Nehaj & Michal Mokan

  2. Department of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59, Martin, Slovakia

    Juraj Sokol, Jela Ivankova, Marian Mokan & Jan Stasko

Authors
  1. Frantisek Nehaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juraj Sokol
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jela Ivankova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michal Mokan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marian Mokan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jan Stasko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juraj Sokol.

Ethics declarations

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patient described in this report.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nehaj, F., Sokol, J., Ivankova, J. et al. Edoxaban affects TRAP-dependent platelet aggregation. J Thromb Thrombolysis 49, 578–583 (2020). https://doi.org/10.1007/s11239-020-02093-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-020-02093-9

Keywords

Search

Navigation